Clinical Trial Update: Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform [Phase 1, Phase 2]

View source ↗

Summary

Phase 1-2 study of temozolomide with hypofractionated radiotherapy for supratentorial glioblastoma multiforme has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Brain and Nervous System
• Glioblastoma

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: Stanford University | Conditions: Glioblastoma, Cancer of Brain and Nervous System | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-07-31